Powell B L, Capizzi R L, Muss H B, Bearden J D, Lyerly E S, Rosenbaum D L, Morgan T M, Richards F, Jackson D V, White D R
Cancer Center, Wake Forest University, Winston-Salem, North Carolina 27103.
Leukemia. 1989 Jan;3(1):23-8.
Forty-four evaluable patients with untreated acute myelogenous leukemia received twice-daily subcutaneous injections of low-dose ara-C (10 mg/m2) for less than or equal to 42 days. The median age was 72 years (range 53-87); 42 of 44 patients were greater than or equal to age 60. Ten patients (23%) had complete responses with a median duration of 9.9 months. Median survival was 3 months (range 0.6-31.2+) for all patients, and 19.5 (range 7.9-31.2+) for patients who attained complete responses. Cytoreduction occurred slowly with low-dose ara-C and five of ten patients who achieved complete remission did not develop marrow aplasia. Toxicity was predominantly related to infections associated with granulocytopenia. Nonhematologic toxicity was limited. Low-dose ara-C as used in this trial results in a complete response rate and a duration of response similar to those achieved with other treatments in elderly patients, but with reduced toxicity.
44例未经治疗的急性髓性白血病患者接受了每日两次皮下注射低剂量阿糖胞苷（10mg/m²），持续时间小于或等于42天。中位年龄为72岁（范围53 - 87岁）；44例患者中有42例年龄大于或等于60岁。10例患者（23%）获得完全缓解，中位缓解持续时间为9.9个月。所有患者的中位生存期为3个月（范围0.6 - 31.2+），达到完全缓解的患者中位生存期为19.5个月（范围7.9 - 31.2+）。低剂量阿糖胞苷导致细胞减少缓慢，10例达到完全缓解的患者中有5例未出现骨髓再生障碍。毒性主要与粒细胞减少相关的感染有关。非血液学毒性有限。本试验中使用的低剂量阿糖胞苷导致的完全缓解率和缓解持续时间与老年患者其他治疗方法相似，但毒性降低。
